US20010014342A1 - Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained - Google Patents

Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained Download PDF

Info

Publication number
US20010014342A1
US20010014342A1 US09735638 US73563800A US20010014342A1 US 20010014342 A1 US20010014342 A1 US 20010014342A1 US 09735638 US09735638 US 09735638 US 73563800 A US73563800 A US 73563800A US 20010014342 A1 US20010014342 A1 US 20010014342A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
skin
substance
ep
composition
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09735638
Inventor
Olivier De La Charriere
Lionel Breton
Original Assignee
Olivier De La Charriere
Lionel Breton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/72Cosmetics or similar toilet preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/731Cellulose; Quaternized cellulose derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/005Preparations for sensitive skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/75Anti-irritant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q1/00Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/14Preparations for removing make-up
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/02Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings containing insect repellants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/004Aftersun preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/02Preparations for cleaning the hair
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/844Cosmetic, facial
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/937Dispersion or emulsion
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/937Dispersion or emulsion
    • Y10S514/938Oil-water type
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/944Gel

Abstract

The invention concerns the use of a substance P antagonist in a cosmetic composition used to treat sensitive skin. More specifically, the invention relates to a substance P antagonist used to prevent and/or combat skin irritations, desquamation, erythemas, sensations of dysesthesia/overheating, or pruritus of the skin.

Description

  • [0001]
    The invention concerns the use of a substance P antagonist in a cosmetic composition used to treat sensitive skin. More specifically, the invention relates to a substance P antagonist used to prevent and/or combat skin irritations, desquamation, erythemas, sensations of dysesthesia/overheating, or pruritus of the skin.
  • [0002]
    The present invention concerns the use of a substance P antagonist in a cosmetic composition used to treat sensitive skin, and the cosmetic composition obtained.
  • [0003]
    It is known that some skin is more sensitive than others. Until now, the symptoms of sensitive skin were poorly characterized, and, accordingly, the problem of sensitive skin was poorly defined. No one knew exactly what process was implicated in skin sensitivity. Some specialists thought that sensitive skin reacted to cosmetic products, while others felt sensitive skin reacted to a number of external factors not necessarily associated with cosmetics.
  • [0004]
    A number of tests were conducted to attempt to identify sensitive skin. For example, these tests made use of lactic acid and DMSO, which are known irritants. (See, for example, the article by K. Lammintausta et al., Dermatoses, 1988, 36, pages 45-49, and the article by T. Agner and J. Serup, Clinical and Experimental Dermatology, 1989, 14, pages 214-217.) However, these tests did not make it possible to characterize sensitive skin.
  • [0005]
    In addition, sensitive skin was held to resemble allergic skin.
  • [0006]
    Because the characteristics features of sensitive skin were poorly known, treatment has proved very difficult until now. Skin was treated indirectly, for example, by restricting the use of irritating products such as surfactants, preservatives, and perfumes in cosmetic compounds.
  • [0007]
    The Applicant conducted numerous clinical tests and was able to determine the symptoms shown in sensitive skin. These symptoms are, in particular, subjective in nature, i.e., basically sensations of dysesthesia. These are more or less painful sensations in a skin area, e.g., tingling, prickling, itching or pruritus, burning, overheating, discomfort, tugging sensations, etc.
  • [0008]
    The Applicant was also able to show that sensitive skin was not allergic skin. Indeed, allergic skin reacts to an external agent, i.e., an allergen, which triggers an allergic reaction. This is an immunological process which occurs only when an allergen is present and which does not affect sensitized subjects. In the Applicant's view, the basic feature of sensitive skin is, on the contrary, a response mechanism to external factors which may affect any individual, even though individuals considered to have sensitive skin react faster than others. This mechanism is not immunological, but aspecific.
  • [0009]
    The Applicant has since discovered that sensitive skin could be divided into two major clinical groups, irritable and/or reactive skin, and intolerant skin.
  • [0010]
    An irritable and/or reactive skin reacts by means of pruritus, that is, by itching or tingling, to various factors such as the environment, emotion, food, wind, friction, shaving, soap, surf actants, hard water having a high limestone concentration, temperature variations, or wool. In general, these signs are associated with dry skin with or without desquamation, or with skin exhibiting erythema.
  • [0011]
    Intolerant skin reacts by producing sensations of overheating, tugging, prickling, and/or redness to various factors such as the environment, emotion, and food. In general, these signs are associated with skin exhibiting hyperseborrhea or acne, with or without desquamation, and with erythema.
  • [0012]
    “Sensitive” scalp has a more pathognomonic clinical semiology: the sensations of pruritus and/or tingling or overheating are triggered basically by localized factors, such as rubbing, soap, surfactants, hard water containing a high limestone concentration, shampoos or lotions. These sensations are sometimes triggered by factors such as the environment, emotion, and/or food. Erythema and hyperseborrhea of the scalp, as well as the presence and extent of dandruff, are frequently associated with the aforementioned signs.
  • [0013]
    Furthermore, in some anatomical regions such as the major bend areas (the inguinal, genital, axillary, popliteal, and submammary regions and the bend of the elbow) and the feet, sensitive skin leads to pruriginous and/or sensations of dysesthesia (overheating, tingling) linked, in particular, to sweat, rubbing, wool, surfactants, hard water containing high limestone concentrations, and/or to temperature variations.
  • [0014]
    To determine whether a particular skin is sensitive or not, the Applicant also perfected a test. In fact, after conducting a large number of tests for the purpose of defining sensitive skin, the Applicant found, surprisingly, that there was link between persons having sensitive skin and those who reacted to a topical application of capsaicin.
  • [0015]
    The capsaicin test is performed by applying, over approximately 4 cm2 of skin, 0.05 ml of a cream containing capsaicin in a concentration of 0.075% and by noting the appearance of subjective signs caused by this application, such as tingling, burning, and itching. In subjects with sensitive skin, these signs appear at between 3 and 20 minutes following application, and are followed by the appearance of an erythema, which begins at the periphery of the area of application.
  • [0016]
    To date, capsaicin has been used as a drug, in particular to treat the pain arising from shingles. Capsaicin causes the release of neuropeptides, in particular tachykinins, which emanate from nerve ends in the epidermis and dermis. The Applicant found that the physiopathological process common to all states of sensitive skin was linked to a pronounced ability to release tachykinins, and, more specifically of substance P, in the skin. The manifestations of dysesthesia caused by their release are termed “neurogenic.”
  • [0017]
    Substance P is a chemical polypeptide produced and released by nerve endings. It belongs to the group of tachykinins. Substance P acts in particular in pain transmission and in diseases of the central nervous system, such as anxiety and schizophrenia, in respiratory, inflammatory, gastrointestinal, and rheumatic diseases, and in certain skin disorders, such as eczema.
  • [0018]
    The Applicant has now discovered that the basic characteristic of sensitive skin is linked to the release of substance P, and thus, that the use of substance P antagonists could produce a preventive and/or curative effect on sensitive skin.
  • [0019]
    To treat sensitive skin, the Applicant thus contemplated the use of substance P antagonists. Indeed, the Applicant found, surprisingly, that the incorporation of a substance P antagonist in a cosmetic compound made it possible to prevent irritation, sensations of dysesthesia, and pruritis in the skin.
  • [0020]
    Therefore, the present invention concerns the use of a substance P antagonist in a composition containing a cosmetically-acceptable medium in order to treat sensitive skin.
  • [0021]
    The present invention further relates to the use of a substance P antagonist to prevent and/or combat skin irritations, desquamation, erythemas, sensations of overheating or of dysesthesia, and/or pruritis in the skin.
  • [0022]
    A cosmetically-acceptable medium is a medium compatible with the skin, the nails, and the hair. The composition containing the substance P antagonist may be applied on the face, the neck, the hair, and the nails, or any other cutaneous region of the body.
  • [0023]
    To be acknowledged as a substance P antagonist, a substance must possess the following characteristics:
  • [0024]
    a selective affinity for the NK1 receptors on the tachykinins;
  • [0025]
    a pharmacological substance P-antagonist action; that is, it must induce a consistent pharmacological response in at least one of the following two tests:
  • [0026]
    the antagonist substance must reduce the extravasation of plasma through the vascular wall caused by the capsaicin or by antidromic nerve excitation, or else
  • [0027]
    the antagonist substance must cause inhibition of the contraction of the smooth muscles caused by administration of substance P.
  • [0028]
    To date, substance P antagonists have been used to treat the diseases indicated above. To this end, reference may be made to the following documents; U.S. Pat. No. 4,472,305, U.S. Pat. No. 4,839,465, EP-A-101929, EP-A-333174, EP-A-336230, EP-A-394989, EP-A-443132, EP-A-498069, EP-A-515681, EP-A-517589, WO-A-92/22569, GB-A-2216529, EP-A-360390, EP-A-429366, EP-A-430771, EP-A-499313, EP-A-514273, EP-A-514274, EP-A-514275, EP-A-514276, EP-A-520555, EP-A-528495, EP-A-532456, EP-A-545478, EP-A-558156, WO-A-90/05525, WO-A-90/05729, WO-A-91/18878, WO-A-91/18899, WO-A-92/12151, WO-A-92/15585, WO-A-92/17449, WO-A-92/20676, WO-A-93/00330, WO-A-93/00331, WO-A-93/01159, WO-A-93/01169, WO-A-93/01170, WO-A-93/06099, WO-A-93/09116, EP-A-522808, and WO-A-93/01165.
  • [0029]
    To date, no one had established a link between substance P and sensitive skin. The clinical signs of sensitive skin are basically subjective: tingling, pricking, pruritis, tugging, and overheating, and they are sometimes associated with erythema. These signs are produced by aspecific external factors. The symptoms are essentially localized on the face, the neck, and the scalp, but may also appear over the entire body.
  • [0030]
    The substance P antagonist according to the invention may be a peptide or a nitrogenous non-peptide derivative, and, more specifically, a compound comprising a nitrogenous heterocyclic compound or an atom of nitrogen bonded directly or indirectly to a benzene ring.
  • [0031]
    In accordance with the invention, use may be made, of example, of sendide or spantide II as a substance P antagonist peptide.
  • [0032]
    Sendide corresponds to the formula:
  • Tyr D—Phe Phe D-—His Leu Met NH2
  • [0033]
    wherein:
  • [0034]
    Tyr is tyrosine
  • [0035]
    D—Phe is D-phenylalanine,
  • [0036]
    Phe is phenylalanine,
  • [0037]
    D—His is D-histidine,
  • [0038]
    Leu is leucine, and
  • [0039]
    Met is methionine.
  • [0040]
    Spantide II corresponds to the formula:
  • D—NicLys Pro 3-Pal Pro D—Cl2Phe Asn D—Trp Phe D—Trp Leu Nle NH2
  • [0041]
    wherein:
  • [0042]
    D—NicLys is D-lysine nicotinate,
  • [0043]
    Pro is proline
  • [0044]
    3-Pal is 3-pyridylalanine,
  • [0045]
    D—Cl2Phe is D-dichlorophenylalanine,
  • [0046]
    Asn is asparagin,
  • [0047]
    D—Trp is D-tryptophan,
  • [0048]
    Phe is phenylalanine,
  • [0049]
    Leu is leucine, and
  • [0050]
    Nle is nor—leucine.
  • [0051]
    According to the invention, the substance P antagonist peptide may also include the peptides described in the following documents: U.S. Pat. No. 4,472,305, U.S. Pat. No. 4,839,465, EP-A-101929, EP-A-333174, EP-A-336230, EP-A-394989, EP-A-443132, EP-A-498069, EP-A-515681, EP-A-517589, WO-A-92/22569, and GB-A-2216529.
  • [0052]
    Non-peptide substance P antagonists that can be used according to the invention include, in particular, compounds containing an atom of nitrogen bonded directly or indirectly to a benzene ring or contained in a heterocyclic compound.
  • [0053]
    As heterocyclic compound, use may be made according to the invention of those heterocyclic compounds described in the following documents: EP-A-360390, EP-A-429366, EP-A-430771, EP-A-499313, EP-A-514273, EP-A-514274, EP-A-514275, EP-A-514276, EP-A-520555, EP-A- 528495, EP-A-532456, EP-A-545478, EP-A-558156, WO-A-90/05525, WO-A-90/05729, WO-A-91/18878, WO-A-91/18899, WO-A-92/12151, WO-A-92/15585, WO-A-92/17449, WO-A-92/20676, WO-A-93/00330, WO-A-93/00331, WO-A-93/01159, WO-A-93/01169, WO-A-93/01170, WO-A-93/06099, and WO-A-93/09116. In particular, the compound containing at least one nitrogenous heterocyclic compound is a derivative of 2-tricyclyl-2-aminoethane, a derivative of spirolactame, a derivative of quinuclidine, an azacyclic derivative, a derivative of aminopyrrolidine, a derivative of piperidine, an aminoazaheterocyclic compound, or a derivative of isoindole.
  • [0054]
    As regards compounds containing a nitrogen atom bonded directly or indirectly to a benzene nucleus, mention may be made of those described in the following documents: EP-A-522808 and WO-A-93/01165.
  • [0055]
    In the compositions according to the invention, the substance P antagonist is preferably used in a quantity ranging from 0.000001 to 5% by weight of the total weight of the composition, and, in particular, in a quantity ranging from 0.0001 to 0.1% by weight of the total weight of the composition.
  • [0056]
    The compositions according to the invention may be present in all galenical forms normally used for topical application, in particular solutions or dispersions of the lotion or serum type, liquid or semi-liquid milk emulsions produced by dispersion of a fatty phase in an aqueous phase (H/E) or the reverse (E/H), or cream- or gel-type emulsions having a soft consistency, or microgranulates or vesicular ionic and/or non-ionic dispersions. These compositions are prepared according to conventional practice.
  • [0057]
    They may also be used for hair, in the form of alcoholic or hydroalcoholic aqueous solutions or as creams, gels, emulsions, or foams, or again, as aerosol compositions also containing a pressurized propulsive agent.
  • [0058]
    The quantities of the various constituents in the compositions according to the invention are those conventionally used in the fields of study under consideration.
  • [0059]
    These compositions make up, in particular, creams for cleansing, protecting, treating, or caring for the face, the hands, the feet, the major anatomical bending areas, or for the body (e.g., day and night creams, make-up removal creams, foundation creams, and sunscreens), liquid foundations, make-up removal lotions, protective or skin-care body lotions, sunscreen lotions, skin-care lotions, gels, or foams, such as cleansing, sunscreen, and artificial tanning lotions, bath preparations, deodorant compositions containing a bactericide, after-shave gels or lotions, depilatory creams, and compositions used for insect stings and against pain.
  • [0060]
    The compositions according to the invention may also consist of solid preparations used for soaps and cleansing bars.
  • [0061]
    In addition, these compositions can be packaged as aerosol compositions also containing a pressurized propulsive agent.
  • [0062]
    The substance P antagonist may also be incorporated into various hair-care compositions, in particular shampoos, setting lotions, treatment lotions, hair creams or gels, coloring compositions (in particular oxidation dyes) potentially in the form of coloring shampoos, restructuring lotions for the hair, permanent compositions (in particular compositions for the first stage of a permanent), anti-hair loss lotions and gels, etc.
  • [0063]
    The cosmetic compositions according to the invention may also be used by mouth, e.g., in toothpastes. In this case, the compositions can contain conventional additives for compositions taken by mouth, in particular surfactants, thickeners, wetting agents, polishing agents such as silica, various active ingredients such as fluorides, in particular sodium fluoride, and potentially, sweeteners such as sodium saccharinate.
  • [0064]
    When the composition according to the invention is an emulsion, the proportion of the fatty phase may range from 5% to 80% by weight, and preferably from 5% to 50% by weight of the total weight of the composition. The oils, emulsifiers, and coemulsifiers used in the emulsion are chosen among those conventionally used in the cosmetic field. The emulsifier and coemulsifier are present in the composition in a proportion of between 0.3% and 30% by weight, and preferably between 0.5% and 30% by weight of the total weight of the composition. Moreover, the emulsion may contain lipidic vesicles.
  • [0065]
    In conventional fashion, the cosmetic composition according to the invention may also contain additives customarily used in cosmetics, such as water-absorbent or lipophilic gelling agents, water-absorbent or lipophilic active ingredients, preservatives, antioxidants, solvents, perfumes, fillers, screens, and coloring substances. The quantities of these various additives are those conventionally used in cosmetics; for example,, from 0.01% to 10% of the total weight of the composition. These additives may, depending on the nature thereof, be added to the fatty phase, the aqueous phase, and/or in lipidic spherules.
  • [0066]
    As regards the oils that can be used according to the invention, mention may be made of mineral oils (vaseline oil), vegetable oils (liquid fraction of karite nut butter, sunflower oil), animal oils (perhydrosqualene), synthetic oils (Purcellin oil), silicone-containing oils (cyclomethicone), and fluorinated oils (perfluoropolyethers). Fatty alcohols and fatty acids (stearic acid) can be added to these oils.
  • [0067]
    Emulsifiers usable according to the invention include, for example, glycerol stearate, polysorbate 60, and the PEG-6/PEG-32/glycol stearate mixture sold under the trade name Tefose® 63 by the Gattefosse Company.
  • [0068]
    Solvents usable according to the invention include the lower alcohols, in particular ethanol and isopropanol.
  • [0069]
    As regards the water-absorbent gelling agents, mention may be made of carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate/alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxylpropylcellulose, natural gums, and clays; and, as regards lipophilic gelling agents, modified clays such as bentonites and the metallic salts of fatty acids, such as aluminum stearates and hydrophobic silica.
  • [0070]
    The water-absorbent active ingredients include proteins and protein hydrolyzates, amino acids, polyalcohols, urea, allantoin, sugars and sugar derivatives, vitamins, and hydroxy acids.
  • [0071]
    The lipophilic active ingredients include retinol (vitamin A) and the derivatives thereof, tocopherol (vitamin E) and the derivatives thereof, essential fatty acids, ceramides, essential oils, and salicylic acid and the derivatives thereof.
  • [0072]
    Substance P antagonists may be combined, among other products, with active ingredients intended, in particular, for the prevention and/or treatment of skin disorders.
  • [0073]
    These active ingredients include, for example:
  • [0074]
    agents modulating the differentiation, proliferation, and/or skin pigmentation, such as retinoic acid and the isomers thereof, retinol and the esters thereof, vitamin D and the derivatives thereof, estrogens such as estradiol, kojik acid and hydroquinone;
  • [0075]
    antibacterial agents such as clindamycin phosphate, erythromycin, antibiotics belonging to the group of tetracyclines;
  • [0076]
    antiparasitic agents, in particular metronidazole, crotamiton, and pyrethrinoids;
  • [0077]
    antifungal agents, in particular the compounds belonging to the imidazoles, such as econazole, ketoconazole, or miconazole and the salts thereof, the polyene compounds, such as amphotericin B, compounds belonging to the group of allylamines, such as terbinafine and octopirox;
  • [0078]
    anti-inflammatory steroid agents, such as hydrocortisone, betamethasone valerate, clobetasol propionate, or non-steroid anti-inflammatory agents such as ibuprofen and the salts thereof, diclofenac and the salts thereof, acetylsalicylic acid, acetaminophen, and glycyrrhetinic acid;
  • [0079]
    anesthetic agents, such as lidocaine chlorhydrate and the derivatives thereof;
  • [0080]
    anti-pruriginous agents, such as thenaldine, trimeprazine, and cyproheptadine;
  • [0081]
    antiviral agents, such as acyclovir;
  • [0082]
    keratolytic agents, such as alpha- and beta-hydroxycarboxylic and beta-ketocarboxylic acids, the salts, amides, and esters thereof, and, more especially, hydroxy acids, such as glycolic, lactic, salicylic, and citric acid, and, in general fruit acids, and n-octanoyl-5-salicylic acid;
  • [0083]
    anti-free radical agents, such as alpha-tocopherol and the esters thereof, superoxide dismutases, some chelating agents of metals, and ascorbic acid and the esters thereof;
  • [0084]
    anti-seborrhea agents, such as progesterone;
  • [0085]
    anti-dandruff products, such as octopirox and zinc pyrithione;
  • [0086]
    acne-fighting products, such as retinoic acid or benzoyl peroxide.
  • [0087]
    Substance P antagonists are advantageously combined with active ingredients producing irritant side effects and widely used in the cosmetics field. The presence of an antagonist in a cosmetic composition containing an active ingredient producing an irritant effect makes it possible to attenuate, and indeed to eliminate, this irritant effect.
  • [0088]
    Accordingly, the invention also concerns a composition containing a cosmetically-acceptable medium and at least one active ingredient producing an irritant side effect, characterized by the fact that it contains a substance P antagonist.
  • [0089]
    In particular, the active ingredients exhibiting irritant side effects are chosen from among the α-hydroxy acids, the β-hydroxy acids, the α-ketonic acids, the β-ketonic acids, retinoids, anthralines, anthranoids, peroxides, minoxidil, lithium salts, antimetabolites, and vitamin D and the derivatives thereof.
  • [0090]
    The present invention further relates to a cosmetic treatment process characterized by the fact that a composition such as that described above and containing at least one substance P antagonist in a cosmetically-acceptable medium is applied on the skin, hair, and/or the mucous membranes.
  • [0091]
    The cosmetic treatment process according to the invention can be implemented, in particular, by applying hygienic or cosmetic compositions such as those specified above, in accordance with method of use normal for these compositions. For example: the application of creams, gels, serums, lotions, make-up removal lotions or sunscreen compositions on the skin or on dry hair, application of a hair lotion on wet hair, shampoos, or application of toothpaste on the gums.
  • [0092]
    The invention also concerns the use of capsaicin for preparing a composition intended to identify sensitive skin, and a process for identifying sensitive skin, which consists in applying a composition containing capsaicin on the skin.
  • [0093]
    The following examples illustrate the invention. In these examples, the proportion indicated are ponderal proportions.
    Example 1: Make-up Removal Face Lotion
    Spantide II 5.00
    Antioxidant 0.05
    Isopropanol 40.00 
    Preservative 0.30
    Water qsp 100%
  • [0094]
    [0094]
    Example 2: Make-up Removal Face Lotion
    Sendide 0.0001
    Antioxidant 0.05
    Isopropanol 40.00
    Preservative 0.30
    Water qsp 100%
  • [0095]
    [0095]
    Example 3: Facial Care Gel
    Spantide II 0.05
    Hydroxypropylcellulose (Klucel H, 1.00
    sold by the Hercules Company)
    Antioxidant 0.05
    Isopropanol 40.00
    Preservative 0.30
    Water qsp 100%
  • [0096]
    [0096]
    Example 4: Facial Care Gel
    Sendide 0.04
    Hydroxypropylcellulose (Klucel H, 1.00
    sold by the Hercules Company)
    Antioxidant 0.05
    Isopropanol 40.00 
    Preservative 0.30
    Water qsp 100%
  • [0097]
    [0097]
    Example 5: Facial Care Cream (oil-in-water emulsion)
    Spantide 0.02
    Glycerol stearate 2.00
    Polysorbate 60 (Tween 60 sold by 1.00
    the ICI Company)
    Stearic acid 1.40
    Triethanolamine 0.70
    Carbomer 0.40
    Liquid fraction of karite nut butter 12.00
    Perhydrosqualene 12.00
    Antioxidant 0.05
    Perfume 0.5
    Preservative 0.30
    Water qsp 100%
  • [0098]
    [0098]
    Example 6: Shampoo
    Spantide II 0.02
    Hydroxypropylcellulose (Klucel H, 1.00
    sold by the Hercules Company) 1.00
    Perfume 0.50
    Preservative 0.30
    Water qsp 100%
  • [0099]
    [0099]
    Example 7: Anti-Wrinkle Facial Cream (oil-in-water emulsion)
    Sendide 0.15
    Glycerol stearate 2.00
    Polysorbate 60 (Tween 60, sold by the 1.00
    ICI Company)
    Stearic acid 1.40
    n-octanoyl-5-salicylic acid 0.50
    Triethanolamine 0.70
    Carbomer 0.40
    Liquid fraction of karite nut butter 12.00
    Perhydrosqualene 12.00
    Antioxidant 0.05
    Perfume 0.50
    Preservative 0.30
    Water qsp 100%
  • [0100]
    [0100]
    Example 8: Shampoo
    Sendide 0.003
    Hydroxypropylcellulose (Klucel H, 1.00
    sold by the Hercules Company)
    Perfume 0.50
    Preservative 0.30
    Water qsp 100%
  • [0101]
    [0101]
    Example 9: Emulsified Gel To Fight Insect Stings (oil-in-water
    emulsion)
    Cyclomethicone 3.00
    Purcellin oil (sold by the Dragocco 7.00
    Company)
    PEG-6/PEG-32/Glycerol Stearate (TefoseR 0.30
    sold by Gattefosse)
    Spantide II 0.02
    Preservative 0.30
    Perfume 0.40
    Carbomer 0.60
    Crotamiton 5.00
    Glycyrrhetinic acid 2.00
    Ethyl alcohol 5.00
    Triethanolamine 0.20
    Water qsp 100%
  • [0102]
    [0102]
    Example 10: Pain-Fighting Gel
    Spantide II 0.03
    Hydroxypropylcellulose (Klucel H, 1.00
    sold by the Hercules Company)
    Antioxidant 0.05
    Lidocaine chlorhydrate 2.00
    Isopropanol 40.00
    Preservative 0.30
    Water qsp 100%
  • [0103]
    [0103]
    Example 11: Anti-Acne Rosacea Face Cream (oil-in-water emulsion)
    Spantide II 0.25
    Glycerol stearate 2.00
    Polysorbate 60 (Tween 60, sold by the 1.00
    ICI Company)
    Stearic acid 1.40
    Metronidazole 1.00
    Triethanolamine 0.70
    Carbomer 0.40
    Liquid fraction of karite nut butter 12.00 
    Vaseline oil 12.00 
    Antioxidant 0.05
    Perfume 0.50
    Preservative 0.30
    Water qsp 100%
  • [0104]
    [0104]
    Example 12: Anti-Solar Erythema Cream (oil-in-water emulsion)
    Spantide II 0.25
    Glycerol stearate 2.00
    Polysorbate 60 (Tween 60, sold by the 1.00
    ICI Company)
    Stearic acid 1.40
    Glycyrrhetinic acid 2.00
    Triethanolamine 0.70
    Carbomer 0.40
    Liquid fraction of karite nut butter 12.00 
    Sunflower oil 10.00 
    Antioxidant 0.05
    Perfume 0.50
    Preservative 0.30
    Water qsp 100%

Claims (24)

  1. 1. Use of a substance P antagonist in a composition containing a cosmetically-acceptable medium for treatment of sensitive skin.
  2. 2. Use according to
    claim 1
    , wherein the substance P antagonist is chosen among the peptides and compounds containing at least one nitrogenous heterocyclic compound.
  3. 3. Use according to
    claim 1
    or
    2
    , wherein the peptide is sendide or spantide II.
  4. 4. Use according to
    claim 1
    or
    2
    , wherein the compound containing at least one nitrogenous heterocyclic compound is a derivative of 2-tricyclyl-2-aminoethane, a derivative of spirolactame, a derivative of quinuclidine, an azacyclic derivative, a derivative of aminopyrrolidine, a derivative of piperidine, an aminoazaheterocyclic compound, or a derivative of isoindole.
  5. 5. Use according to any of the preceding claims, wherein the substance P antagonist is used in a quantity of between 0.000001 to 5% by weight of the total weight of the composition.
  6. 6. Use according to any of the preceding claims, wherein the substance P antagonist is used in a quantity of between 0.0001 to 0.1% of the total weight of the composition.
  7. 7. Use according to any of the preceding claims, wherein the cosmetically-acceptable medium is an aqueous or hydroalcoholic solution, a water-in-oil or oil-in-water emulsion, a microemulsion, an aqueous gel, an anhydrous gel, a serum, or a vesicular dispersion.
  8. 8. Use according to any of the preceding claims, wherein the composition contains at least one agent chosen from among antibacterial, anti-parasitical, anti-fungal, anti-inflammatory, anti-pruriginous, anesthetic, antiviral, keratolytic, anti-free radical, anti-seborrhea, dandruff-fighting, and acne-fighting agents and/or agents modulating skin differentiation, proliferation, and/or pigmentation.
  9. 9. Use according to the preceding claim, wherein the agent is lidocaine chlorhydrate, or a non-steroid anti-parasitical or anti-inflammatory agent.
  10. 10. Use in a cosmetic composition of a substance P antagonist to prevent and/or combat skin irritations, desquamation, erythemas, sensations of dysesthesia, sensations of overheating, and/or pruritis of the skin.
  11. 11. Use according to
    claim 10
    , wherein the substance P antagonist is chosen from among peptides and compounds containing at least one nitrogenous heterocyclic compound.
  12. 12. Use according to
    claim 10
    or
    11
    , wherein the substance P antagonist is used in a quantity of between 0.000001 and 5% by weight of the total weight of the composition.
  13. 13. Use according to any of
    claims 10
    to
    12
    , wherein the substance P antagonist is used in a quantity of between 0.0001 and 0.1% by weight of the total weight of the composition.
  14. 14. Cosmetic treatment process, wherein a composition containing a substance P antagonist in a cosmetically-acceptable medium is applied on the skin, hair, and/or mucous membranes.
  15. 15. Process according to
    claim 14
    , wherein the substance P antagonist is chosen from among the peptides and compounds containing at least one nitrogenous heterocyclic compound.
  16. 16. Process according to
    claim 14
    or
    15
    , wherein the substance P antagonist is used in a quantity of between 0.000001 to 5% by weight of the total weight of the composition.
  17. 17. Process according to any of
    claims 14
    to
    16
    , wherein the substance P antagonist is used in a quantity of between 0.0001 and 0.1% by weight of the total weight of the composition.
  18. 18. Cosmetic composition containing a cosmetically-acceptable medium and at least one active ingredient producing an irritant side effect, wherein said composition contains a substance P antagonist.
  19. 19. Cosmetic composition according to
    claim 18
    , wherein the substance P antagonist is chosen from among the peptides and compounds containing at least one nitrogenous heterocyclic compound.
  20. 20. Cosmetic composition according to
    claim 18
    or
    19
    , wherein the substance P antagonist is used in a quantity of between 0.000001 and 5% by weight of the total weight of the composition.
  21. 21. Cosmetic composition according to any of
    claims 18
    to
    20
    , wherein the substance P antagonist is used in a quantity of between 0.0001 and 0.1% by weight of the total weight of the composition.
  22. 22. Cosmetic composition according to any of
    claims 18
    to
    21
    , wherein the active ingredient producing an irritant side effect is chosen from among α-hydroxy acids, β-hydroxy acids, α-ketonic acids, β-ketonic acids, retinoids, anthralines, anthranoids, peroxides, minoxidil, lithium salts, antimetabolites, and vitamin D and the derivatives thereof.
  23. 23. Cosmetic composition according to any of
    claims 18
    to
    22
    , wherein said cosmetic composition further contains at least one agent selected from among antibacterial, anti-parasitical, antifungal, anti-inflammatory, anti-pruriginous, anesthetic, antiviral, keratolytic, anti-free radical, anti-seborrhea, dandruff-fighting, and acne-fighting agents and/or agents modulating skin differentiation, proliferation, and/or pigmentation.
  24. 24. Use of capsaicin for preparation of a composition intended to identify sensitive skin.
US09735638 1994-05-05 2000-12-14 Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained Abandoned US20010014342A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR9405537A FR2719474B1 (en) 1994-05-05 1994-05-05 Use of a substance P antagonist in a cosmetic composition and resulting composition.
FR9405537 1994-05-05
US35856294 true 1994-12-14 1994-12-14
US08611549 US6235291B1 (en) 1994-05-05 1996-03-11 Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
US09735638 US20010014342A1 (en) 1994-05-05 2000-12-14 Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09735638 US20010014342A1 (en) 1994-05-05 2000-12-14 Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08611549 Continuation US6235291B1 (en) 1994-05-05 1996-03-11 Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained

Publications (1)

Publication Number Publication Date
US20010014342A1 true true US20010014342A1 (en) 2001-08-16

Family

ID=9462919

Family Applications (2)

Application Number Title Priority Date Filing Date
US08611549 Expired - Lifetime US6235291B1 (en) 1994-05-05 1996-03-11 Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
US09735638 Abandoned US20010014342A1 (en) 1994-05-05 2000-12-14 Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08611549 Expired - Lifetime US6235291B1 (en) 1994-05-05 1996-03-11 Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained

Country Status (7)

Country Link
US (2) US6235291B1 (en)
EP (1) EP0680749B1 (en)
JP (1) JP2783520B2 (en)
CA (1) CA2148652C (en)
DE (2) DE69504567D1 (en)
ES (1) ES2123922T3 (en)
FR (1) FR2719474B1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180033A1 (en) * 1998-10-05 2004-09-16 Laboratoires Pharmascience Cosmetic method for preventing and/or treating skin stretchmarks, and use in dermatology
US20090087396A1 (en) * 2004-04-22 2009-04-02 Coty B.V. Sweat-Absorbing Cosmetic Product and Method for the Production Thereof
US20090220555A1 (en) * 2004-04-22 2009-09-03 Coty B.V. Sweat-Absorbing Cosmetic Product and Method for the Production Thereof
US20110039801A1 (en) * 2006-10-16 2011-02-17 Lion Corporation Nk1 receptor antagonist composition

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728165B1 (en) 1994-12-19 1997-02-07
US5672640A (en) * 1995-07-12 1997-09-30 Caschem, Inc. Polypropylene compatible grease compositions for optical fiber cable
DE69601765T2 (en) * 1995-09-07 1999-07-08 Oreal Extract of Iridaceae and compositions containing it
FR2738741B1 (en) * 1995-09-19 1997-12-05 Oreal Composition for dyeing keratin fibers, containing a substance P antagonist
FR2740040B1 (en) * 1995-10-23 1997-12-05 Oreal Use of at least one beta-adrenergic agonist as an antagonist of substance P.
FR2740332B1 (en) * 1995-10-26 1997-12-05 Oreal Composition for permanently reshaping keratin fibers, containing a substance P antagonist or an antagonist of CGRP
FR2741262B1 (en) * 1995-11-20 1999-03-05 Oreal Use of a TNF-alpha antagonist for the treatment of skin redness of neurogenic origin
FR2741802B1 (en) * 1995-12-04 1998-01-02 Oreal Use of melatonin for treating sensitive skins
FR2743813B1 (en) 1996-01-23 1998-02-20 Oreal Stable gelled composition has a high content of electrolyte
FR2746007B1 (en) 1996-03-12 1998-04-24 Stable gelled composition has a high content of electrolyte and its use in cosmetic, pharmaceutical and / or dermatological
FR2746647B1 (en) * 1996-03-27 1998-05-15 Oreal soothing composition comprising an extract of Iridaceae
FR2746642B1 (en) * 1996-03-27 1998-05-15 Oreal soothing composition comprising a bacterial extract
US6776980B1 (en) 1996-07-01 2004-08-17 L'oreal Photoprotective/cosmetic compositions comprising dibenzoylmethane/triazine/diphenylacrylate compounds
FR2768624B1 (en) * 1997-09-25 1999-11-12 Oreal Use of an excitatory amino acid inhibitor in a cosmetic or dermatological composition for sensitive skin composition obtained
JP4447685B2 (en) * 1999-01-14 2010-04-07 第一三共株式会社 Dry skin disease treatment
JP2001233764A (en) * 2000-02-22 2001-08-28 Hisamitsu Pharmaceut Co Inc Antipruritic agent comprising n-substituted-o-toluidine derivative
US20030225326A1 (en) * 2002-04-03 2003-12-04 Bernard Querleux Methods and combinations relating to information obtained using brain imaging techniques
DE10223221A1 (en) * 2002-05-24 2003-12-11 Sebapharma Gmbh & Co Kg A cosmetic composition with hautentquellender effect
FR2841136B1 (en) * 2002-06-25 2004-08-13 Oreal Method of non-therapeutic assessment of neuro-cutaneous sensitivity kit and use the kit to implement the PROCESS
US8100830B2 (en) 2002-06-25 2012-01-24 Societe L'oreal S.A. Non-therapeutic methods of evaluating skin neurosensitivity, kit and use of a kit for implementing the method
US7300649B2 (en) 2005-02-11 2007-11-27 Genepharm, Inc. Cosmetic and cosmeceutical compositions for restoration of skin barrier function
US20070154448A1 (en) * 2005-11-22 2007-07-05 Ted Reid Methods and compositions using Substance P to promote wound healing
WO2007100874A3 (en) 2006-02-28 2008-10-16 Avon Prod Inc Compositions containing peptides with non-natural amino acids and methods of use
FR2918883B1 (en) 2007-07-17 2010-01-15 Oreal Use of a bacterial extract grown on a hot water for the treatment of dry skin
WO2011010075A1 (en) 2009-07-24 2011-01-27 L'oreal Use of jasmonic acid derivative as a soothing agent
FR2968952A1 (en) 2010-12-17 2012-06-22 Oreal amine acid ester n-acyl way of soothing agent

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3266934A (en) * 1962-12-04 1966-08-16 John R Alexander Removal of contaminants from interiors of enclosures
US3772431A (en) * 1972-09-21 1973-11-13 W Mlkvy Effervescent mouthwash tablet
US3888976A (en) * 1972-09-21 1975-06-10 William P Mlkvy Zinc and strontium ion containing effervescent mouthwash tablet
US4980184A (en) * 1987-02-04 1990-12-25 Boliden Kemi Aktiebolag Method and agent for preservation of hay
US4986981A (en) * 1986-07-07 1991-01-22 Den Mat Corporation Toothpaste having low abrasion
US5091171A (en) * 1986-12-23 1992-02-25 Yu Ruey J Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use
US5202130A (en) * 1989-08-31 1993-04-13 The Johns Hopkins University Suppression of eczematous dermatitis by calcium transport inhibition
US5658581A (en) * 1994-12-28 1997-08-19 L'oreal Histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist in a cosmetic, pharmaceutical or dermatological composition and composition obtained
US5679360A (en) * 1994-12-19 1997-10-21 L'oreal Substance P antagonist for the treatment of lichens, prurigo, pruritus
US5714155A (en) * 1994-12-19 1998-02-03 Societe L'oreal S.A. Ethylenediamine derivative in a cosmetic or dermatological composition, and composition containing in particular a product having an irritant side effect
US5716625A (en) * 1994-12-21 1998-02-10 Cosmederm Technologies Formulations and methods for reducing skin irritation

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE297062C (en)
LU65373A1 (en) 1972-05-17 1973-11-23
JPS58501675A (en) * 1981-10-09 1983-10-06
JP2519024B2 (en) 1982-06-07 1996-07-31 花王株式会社 Hair cosmetics
DE3338957A1 (en) 1983-10-27 1985-05-15 Keyhan Dipl Ing Ghawami Depilatory composition
US4837026A (en) 1985-10-03 1989-06-06 Rajakhyaksha Vithal J Transdermal and systemic preparation and method
DE3627746A1 (en) 1986-08-16 1988-02-18 Henkel Kgaa Method for permanent hair deformation
CA1330562C (en) * 1987-07-14 1994-07-05 David Thomas Connor Benzothiophenes having antiallergic activity and both novel and other selected benzothiophenes having activity for treating acute respiratory distress syndrome
EP0360390A1 (en) * 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
CA2014201A1 (en) 1989-04-26 1990-10-26 Albemarle Corporation Solid non-hygroscopic trialkylamine oxides
FR2654725B1 (en) * 1989-11-23 1992-02-14 Rhone Poulenc Sante New derivatives isoindolone, their preparation and pharmaceutical compositions containing them.
EP0439640B1 (en) 1990-01-29 1993-09-15 WOGEPHARM GmbH Method for preparing agents for the therapy of skin diseases
DE69105131T2 (en) * 1990-06-01 1995-03-23 Pfizer 3-amino-2-arylchinuclidine, processes for their preparation and pharmaceutical compositions containing them.
JPH0525850B2 (en) 1990-06-13 1993-04-14 Kao Corp
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
FR2676442B1 (en) * 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa New derivatives perhydroisoindole, their preparation and pharmaceutical compositions containing them.
FR2677361B1 (en) * 1991-06-04 1995-04-14 Adir
US5288730A (en) * 1991-06-24 1994-02-22 Merck Sharp & Dohme Limited Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
JPH06509087A (en) 1991-07-05 1994-10-13
CA2110513A1 (en) 1991-07-05 1993-01-21 Christopher J. Swain Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
JPH06509090A (en) 1991-07-10 1994-10-13
WO1993001159A1 (en) * 1991-07-10 1993-01-21 Merck Sharp & Dohme Limited Fused tricyclic compounds, pharmaceutical compositions containing them and their use in therapy
DE69210029T2 (en) * 1991-08-20 1997-01-09 Merck Sharp & Dohme Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
EP0545478A1 (en) * 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
GB9201179D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
JPH05339240A (en) * 1992-06-04 1993-12-21 Yamanouchi Pharmaceut Co Ltd Tetrahydroisoquinoline amide derivative
DE9211006U1 (en) 1992-08-17 1993-12-16 Kao Corp Gmbh Hair-treatment
GB9222486D0 (en) * 1992-10-26 1992-12-09 Merck Sharp & Dohme Therapeutic agents
CA2114968A1 (en) 1993-02-25 1994-08-26 John Wille Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
US5492927A (en) 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
EP0799018A4 (en) 1994-12-21 2000-03-29 Cosmederm Technologies Formulations and methods for reducing skin irritation
CA2208268A1 (en) 1994-12-21 1996-06-27 Cosmederm Technologies Formulations and methods for reducing skin irritation
DK0801554T3 (en) 1994-12-21 2003-08-04 Cosmederm Technologies Formulations and methods for reducing the skin irritation
US5756107A (en) 1994-12-21 1998-05-26 Cosmederm Technologies Formulations and methods for reducing skin irritation
FR2740332B1 (en) 1995-10-26 1997-12-05 Oreal Composition for permanently reshaping keratin fibers, containing a substance P antagonist or an antagonist of CGRP

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3266934A (en) * 1962-12-04 1966-08-16 John R Alexander Removal of contaminants from interiors of enclosures
US3772431A (en) * 1972-09-21 1973-11-13 W Mlkvy Effervescent mouthwash tablet
US3888976A (en) * 1972-09-21 1975-06-10 William P Mlkvy Zinc and strontium ion containing effervescent mouthwash tablet
US4986981A (en) * 1986-07-07 1991-01-22 Den Mat Corporation Toothpaste having low abrasion
US5091171A (en) * 1986-12-23 1992-02-25 Yu Ruey J Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5091171B1 (en) * 1986-12-23 1995-09-26 Ruey J Yu Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use
US4980184A (en) * 1987-02-04 1990-12-25 Boliden Kemi Aktiebolag Method and agent for preservation of hay
US5202130A (en) * 1989-08-31 1993-04-13 The Johns Hopkins University Suppression of eczematous dermatitis by calcium transport inhibition
US5679360A (en) * 1994-12-19 1997-10-21 L'oreal Substance P antagonist for the treatment of lichens, prurigo, pruritus
US5714155A (en) * 1994-12-19 1998-02-03 Societe L'oreal S.A. Ethylenediamine derivative in a cosmetic or dermatological composition, and composition containing in particular a product having an irritant side effect
US5716625A (en) * 1994-12-21 1998-02-10 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5658581A (en) * 1994-12-28 1997-08-19 L'oreal Histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist in a cosmetic, pharmaceutical or dermatological composition and composition obtained

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180033A1 (en) * 1998-10-05 2004-09-16 Laboratoires Pharmascience Cosmetic method for preventing and/or treating skin stretchmarks, and use in dermatology
US8466109B2 (en) 1998-10-05 2013-06-18 Laboratoires Expanscience Cosmetic method for preventing and/or treating skin stretchmarks, and use in dermatology
US20090087396A1 (en) * 2004-04-22 2009-04-02 Coty B.V. Sweat-Absorbing Cosmetic Product and Method for the Production Thereof
US20090220555A1 (en) * 2004-04-22 2009-09-03 Coty B.V. Sweat-Absorbing Cosmetic Product and Method for the Production Thereof
US8900609B2 (en) 2004-04-22 2014-12-02 Coty B.V. Sweat-absorbing cosmetic product and method for the production thereof
US20110039801A1 (en) * 2006-10-16 2011-02-17 Lion Corporation Nk1 receptor antagonist composition
US8426386B2 (en) 2006-10-16 2013-04-23 Lion Corporation NK1 receptor antagonist composition

Also Published As

Publication number Publication date Type
EP0680749A2 (en) 1995-11-08 application
JPH07304649A (en) 1995-11-21 application
JP2783520B2 (en) 1998-08-06 grant
FR2719474A1 (en) 1995-11-10 application
DE69504567T2 (en) 1999-02-04 grant
US6235291B1 (en) 2001-05-22 grant
DE69504567D1 (en) 1998-10-15 grant
EP0680749B1 (en) 1998-09-09 grant
ES2123922T3 (en) 1999-01-16 grant
FR2719474B1 (en) 1996-05-31 grant
CA2148652C (en) 2002-12-17 grant
CA2148652A1 (en) 1995-11-06 application
EP0680749A3 (en) 1996-09-11 application

Similar Documents

Publication Publication Date Title
US6433003B1 (en) Method for treating hyperhidrosis in mammals
US5961997A (en) Antipruritic composition
US5496827A (en) Compositions for the transdermal delivery of nutrients
US4707354A (en) Mature skin treatment and protectant compositions and methods of using same
US5560916A (en) Cosmetic composition containing vinegar as active anti-ageing agent, and its use in the treatment of dermatological ageing
US5296476A (en) Skin care compositions
US6709663B2 (en) Multivesicular emulsion drug delivery systems
US5866168A (en) Dermatological/pharmaceutical compositions comprising lanthanide, manganese, tin, zinc, yttrium, cobalt, barium and/or strontium salts as substance P antagonists
US20030026820A1 (en) Use of a compositon containing an effective quantity of at least one ion chelating agent for increasing the tolerance threshold of a sensitive or intolerant skin
US5976559A (en) Compositions and methods for treating wrinkles and/or fine lines of the skin
US7083799B1 (en) No-synthase inhibitors
US6139850A (en) Formulations and methods for reducing skin irritation
US5716625A (en) Formulations and methods for reducing skin irritation
US5756107A (en) Formulations and methods for reducing skin irritation
US5958436A (en) Formulations and methods for reducing skin irritation
US5621008A (en) N-acyl-ethylene-triacetic acids
US5788956A (en) Antiperspirant compositions comprising substance P antagonists
US6344461B1 (en) Treating skin wrinkles/fine lines with calcium channel inhibitors
US5804203A (en) Topical product formulations containing strontium for reducing skin irritation
US20070232574A1 (en) 2-Oxothiazolidine 4-Carboxylic acid compounds for promoting desquamation of the skin
US20050136085A1 (en) Panthenol and natural organic extracts for reducing skin irritation
US5795574A (en) Use of an extract from a non-photosynthetic filamentous bacterium and composition containing it
US5993833A (en) Histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist in a cosmetic, pharmaceutical or dermatological composition
WO2004101609A2 (en) Cosmetic or dermopharmaceutical composition for reducing the signs of cutaneous ageing
US6509014B1 (en) Therapeutic/cosmetic compositions comprising CGRP antagonists for treating skin redness/rosacea/discreet erythema